7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 
      
    		                                
      operating activities
    		                                
      net income
    		-52,904,000 -46,632,000 -49,498,000 -43,292,000 -43,677,000 -32,261,000 -141,372,000 -41,633,000 -44,163,000 -46,703,000 -52,179,000 -42,493,000 -40,861,000 -45,001,000 -52,764,000 -42,866,000 -35,107,000 -35,389,000 43,750,000 -34,897,000 -33,818,000 -31,117,000 -34,164,000 -32,956,000 -36,003,000 -42,796,000 -28,974,000 -25,507,000 -17,686,000 -14,412,000 -16,459,000  
      adjustments to reconcile net income to net cash from operating activities:
    		                                
      stock-based compensation expense
    		18,810,000 15,880,000 12,862,000 10,556,000 11,001,000 10,358,000 7,767,000 8,674,000 8,612,000 8,891,000 6,376,000 5,287,000 4,796,000 5,137,000 4,611,000 4,676,000 5,268,000 5,669,000 5,191,000 4,257,000 4,695,000 3,028,000 5,475,000 2,924,000 3,035,000 3,272,000 2,644,000 2,023,000 1,893,000 1,516,000 958,000  
      depreciation and amortization
    		304,000 379,000 383,000 383,000 385,000 390,000 405,000 417,000 442,000 442,000 457,000 442,000 442,000 438,000 350,000 325,000 315,000 317,000 201,000 178,000 172,000 173,000 167,000 191,000 191,000 207,000 245,000 214,000 106,000 61,000 61,000  
      non-cash interest expense
    		4,742,000 5,818,000 5,408,000 8,413,000 4,203,000                            
      non-cash accretion & amortization of short-term investments
    		-1,695,000 -1,179,000 -1,787,000 -2,138,000 -2,465,000 -1,507,000 -2,055,000                          
      non-cash rent expense
    		104,000 105,000 110,000 111,000 108,000 70,000 111,000 107,000 102,000 98,000 94,000 -69,000 -68,000 -65,000 -65,000 -65,000 -63,000 -61,000 -61,000   -58,000 -56,000 -58,000 8,000 151,000 102,000 84,000 17,000 -20,000 -20,000  
      change in fair value of embedded derivative liability
    		-360,000 -500,000 80,000 -120,000 -510,000 -300,000 -490,000 -40,000 -130,000 30,000 -50,000                      
      gain on settlement of forward contract
    		   0 0                            
      acquired ipr&d assets classified as investing activities
    		   0 0 0 92,385,000 0 17,000 255,000 5,395,000                      
      foreign currency (gain) loss
    		1,270,000                                
      changes in operating assets and liabilities:
    		                                
      accounts receivable
    		-6,600,000 -7,832,000 687,000 794,000 -1,708,000 -2,903,000 172,000 -326,000 -710,000 -5,714,000 -1,893,000                      
      inventory
    		-2,451,000 479,000 -575,000 -4,846,000 -1,901,000 -3,487,000 117,000 -862,000 -1,585,000 -690,000 -2,570,000                      
      prepaid expenses and other current assets
    		6,385,000 -6,801,000 -3,204,000 -5,705,000 -106,000 2,708,000 -2,421,000 5,243,000 497,000 -2,678,000 -186,000 -744,000 -492,000 -1,530,000 950,000 -6,191,000 2,965,000 -3,025,000 1,651,000 -541,000 1,444,000 495,000 -847,000 -1,786,000 -544,000 -727,000 -3,321,000 -3,526,000 -1,927,000 -1,414,000 581,000  
      deferred revenue
    		0 0 -1,286,000     0 0 -142,000 -6,000 -7,080,000 -549,000                    
      other long-term assets
    		-5,242,000 5,424,000 102,000 4,786,000 908,000 1,054,000 1,195,000 -4,000 537,000 1,222,000 -99,000 1,000 -870,000 2,690,000 -6,661,000 -1,282,000                 
      accounts payable, accrued expenses and other liabilities
    		11,015,000 13,255,000 -3,633,000 15,179,000 7,508,000 482,000 -1,251,000 4,858,000 4,087,000 661,000 5,167,000                      
      net cash from operating activities
    		-26,622,000 -23,313,000 -40,351,000 -18,845,000 -25,215,000 -29,076,000 -40,743,000 -29,383,000 -29,251,000 -41,090,000 -36,433,000 -34,000,000 -46,987,000 -38,809,000 -53,632,000 -40,472,000 -40,160,000 -31,840,000 -33,531,000 -29,123,000 -27,030,000 -29,729,000 -36,098,000 -32,221,000 -33,605,000 -25,546,000 -31,378,000 -20,983,000 -16,942,000 -12,480,000 -11,651,000  
      capex
    		0 0 0 0 0 0 0 1,000 -1,000 0 -47,000 1,000 -95,000 -60,000 -127,000 -68,000 -106,000 -248,000 -12,000 -84,000 0 0 0 0 -259,000 -2,315,000 -811,000 -395,000 -317,000 0 0  
      free cash flows
    		-26,622,000 -23,313,000 -40,351,000 -18,845,000 -25,215,000 -29,076,000 -40,743,000 -29,382,000 -29,252,000 -41,090,000 -36,480,000 -33,999,000 -47,082,000 -38,869,000 -53,759,000 -40,540,000 -40,266,000 -32,088,000 -33,543,000 -29,207,000 -27,030,000 -29,729,000 -36,098,000 -32,221,000 -33,864,000 -27,861,000 -32,189,000 -21,378,000 -17,259,000 -12,480,000 -11,651,000  
      investing activities
    		                                
      purchases of short-term investments
    		-267,847,000 -26,954,000 -33,521,000 -66,378,000 -135,623,000   -40,653,000 -169,187,000 -75,434,000 -69,644,000 -100,416,000 -101,081,000 -10,961,000 -39,479,000 -68,734,000 -93,769,000 -64,927,000 -297,542,000 -33,471,000 -9,985,000 -28,043,000 -15,370,000 -184,877,000 -41,073,000 -14,056,000 -55,819,000 -60,033,000 -168,150,000 -18,386,000 -2,023,000  
      maturities of short-term investments
    		61,500,000 80,989,000 58,333,000 87,535,000 45,305,000 57,750,000 70,050,000 63,292,000 74,500,000 124,500,000 92,675,000 59,640,000 61,479,000 51,000,000 112,128,000 69,050,000 156,655,000 83,700,000 51,842,000 95,442,000 45,025,000 60,904,000 44,243,000 45,750,000 82,803,000 62,516,000 80,171,000 72,703,000 32,000,000 34,833,000 22,630,000  
      acquisition of ipr&d assets
    		   0 -500,000 0 -40,000,000                          
      net cash from investing activities
    		-246,347,000 54,035,000 24,812,000 21,157,000 -90,818,000 -8,562,000 30,050,000 22,640,000 -94,960,000 48,191,000 18,464,000 -40,775,000 -39,697,000 35,979,000 72,522,000 7,248,000 62,780,000 13,525,000 -145,712,000 61,887,000 34,910,000 32,861,000 28,873,000 -139,127,000 41,471,000 46,145,000 23,541,000 12,275,000 -136,467,000 16,437,000 20,607,000  
      financing activities
    		                                
      repayment of deferred royalty obligation
    		-5,570,000 -4,332,000 -4,615,000 -3,808,000 -3,336,000 -2,973,000 -2,783,000    -1,351,000                      
      proceeds from issuance of common stock upon completion of public offering, net of offering costs
    		                                
      proceeds from the exercise of stock options
    		5,486,000 3,443,000 2,226,000 2,990,000 5,231,000 1,402,000 6,353,000 4,997,000 1,577,000 341,000 553,000 5,889,000    105,000 180,000 383,000 3,466,000 420,000 501,000 183,000 383,000 611,000 434,000 498,000 21,000 174,000 1,308,000    
      proceeds from issuance of common stock from espp
    		729,000 0 854,000 0 597,000 0 673,000 0 388,000 0 665,000 0 227,000 0 399,000 0 233,000 0 388,000 0 198,000 0 324,000 0 263,000 0 295,000      
      proceeds from series a preferred stock, net of issuance costs
    		   0 0                            
      proceeds from atm equity offering
    		1,000 0 34,034,000                              
      net cash from financing activities
    		189,301,000 -889,000 32,499,000 38,328,000 2,492,000 146,179,000 4,243,000 2,423,000 73,043,000 -965,000 -133,000 17,365,000 158,564,000 37,500,000 399,000 100,000 413,000 383,000 165,585,000 420,000 699,000 183,000 707,000 161,963,000 697,000 498,000 316,000 153,000 1,173,000    
      effect of exchange rates on cash
    		304,000 -279,000 -2,000 977,000 -603,000 -301,000 -71,000 -192,000 77,000 -113,000 86,000                      
      net increase in cash, cash equivalents and restricted cash
    		-83,364,000 29,554,000 16,958,000 41,618,000 -114,145,000   -4,512,000 -51,091,000 6,023,000 -18,016,000 -57,410,000 71,880,000 34,670,000 19,289,000 -33,124,000    33,184,000 8,579,000 3,315,000 -6,518,000 -9,385,000 8,563,000 21,097,000 -7,521,000 -8,555,000 -152,236,000 167,317,000 8,956,000  
      cash, cash equivalents and restricted cash at beginning of period
    		0 0 89,601,000 0 0 0 60,409,000 0 0 0 128,005,000 0 0 0 59,576,000 0 0 0 101,257,000 0     0 0 49,943,000 0 0    
      cash, cash equivalents and restricted cash at end of period
    		-83,364,000 29,554,000 106,559,000 41,618,000 -114,145,000 108,240,000 53,888,000 -4,512,000 -51,091,000 6,023,000 109,989,000 -57,410,000 71,880,000 34,670,000 78,865,000 -33,124,000 23,033,000 -17,932,000 87,599,000 33,184,000     8,563,000 21,097,000 42,422,000 -8,555,000 -152,236,000    
      supplemental disclosure of non-cash investing and financing activities:
    		                                
      non-current liability issued in exchange for the acquisition of ipr&d
    		   0 0 0 33,669,000                          
      issuance of common stock in exchange for ipr&d
    		   0 0 0 18,716,000                          
      accretion of preferred stock dividends
    		1,375,000 1,349,000 1,322,000 1,339,000 1,329,000                            
      loss on rarestone equity investment
    		           0                     
      payment of milestone obligation under license agreement
    		           0                     
      purchases of property and equipment
    		       1,000 -1,000 0 -47,000 1,000 -95,000 -60,000 -127,000 -68,000 -106,000 -248,000 -12,000 -84,000    0 -259,000 -2,315,000 -811,000      
      net proceeds from issuance of common stock
    		       0    14,138,000    -5,000 0 0 161,731,000         -21,000 -135,000    
      proceeds from royalty financing agreement, net of issuance costs
    		       0                         
      non-cash accretion of other current liability
    		                                
      non-cash accretion of non-current liability
    		     998,000 929,000                          
      holdback payable associated with acquisition of ipr&d assets, in accrued expenses
    		                                
      transaction costs associated with acquisition of ipr&d assets, in accounts payable
    		                                
      non-cash interest expense and amortization of debt issuance costs
    		      4,009,000 4,018,000 3,148,000 3,133,000 3,061,000 3,199,000                     
      unrealized loss on short-term investments
    		      -244,000                          
      net decrease in cash, cash equivalents and restricted cash
    		      -6,521,000           -17,932,000 -13,658,000              
      supplemental disclosure of non-cash investing activities:
    		                                
      gain on sale of priority review voucher
    		               0 0 0 -100,000,000              
      proceeds from sale of priority review voucher
    		               0 0 0 100,000,000              
      proceeds from out-license agreement
    		                                
      acquisition of ipr&d assets, including transaction costs
    		       0 -272,000 -875,000 -4,520,000                      
      ​
    		                                
      repayments on deferred royalty obligation
    		        -2,167,000                        
      deferred financing costs in accrued expenses
    		            -354,000                    
      unrealized gain on short-term investments
    		                                
      holdback payable associated with the acquisition, in accrued expenses
    		         0 500,000                      
      transaction costs associated with the acquisition, in accounts payable
    		         -120,000 375,000                      
      accounts payable, accrued expenses and other current liabilities
    		           15,712,000 -12,569,000 -1,547,000 -53,000 12,920,000 5,990,000 5,671,000 -6,269,000 1,941,000 536,000 -2,250,000 -6,673,000 -536,000 -1,230,000 14,347,000 -2,074,000 5,729,000 655,000 1,789,000 -1,220,000  
      deferred tax provision
    		                -8,995,000 -5,022,000 22,006,000              
      proceeds from royalty financing agreement
    		            37,500,000                    
      supplemental disclosures:
    		                                
      amortization of debt issuance costs
    		                                
      milestone obligation under license agreement
    		               0 0                
      adjustments to reconcile net income to cash from operating activities:
    		                                
      non-cash research and development license expense
    		                           0 0 0 4,448,000  
      deferred rent
    		                                
      tenant improvement allowance
    		                       0         
      deferred rent expense
    		                                
      cash, cash equivalents and restricted cash at beginning of year
    		                     0 62,697,000        34,461,000  
      cash, cash equivalents and restricted cash at end of year
    		                     3,315,000 56,179,000        43,417,000  
      mark to market revaluation of series a investor instrument
    		                                
      deferred issuance costs
    		                                
      due to related party
    		                                
      net proceeds from issuance of series a convertible preferred stock
    		                                
      deferred grant income
    		                                
      due to related parties
    		                                
      purchases of property, plant and equipment
    		                           -395,000 -317,000    
      net cash provided by:
    		                                
      net increase in cash and cash equivalents
    		                               6,322,000 
      cash and cash equivalents at beginning of period
    		                                
      cash and cash equivalents at end of period
    		                                
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.